Key Highlights
- Third quarter Revenue reached USD 25.8 million, far above the USD 5.1 million estimate, led by first veligrotug product sales.
- Loss per share of USD 0.81 beat the USD 1.02 estimate but widened from USD 0.34 a year earlier.
- Selling, general and administrative costs more than doubled to USD 57.6 million as headcount grew for the commercial launch.
- Cash, equivalents and marketable securities totaled USD 955.2 million, enough to fund planned operations for at least twelve months.
Viridian Therapeutics (NASDAQ:VRDN) reported third quarter revenue of USD 25.75 million, compared with a USD 5.09 million estimate and USD 70.57 million a year earlier, when a one-time USD 70.0 million license payment from Kissei inflated the base. The net loss per share of USD 0.81 was narrower than the USD 1.02 estimate. The quarter was the first with commercial sales, following the June approval of veligrotug, marketed as Lumvoa, for thyroid eye disease.
Product Sales Replace License Income
Net product revenue was USD 24.7 million, or about 96% of the total, against none a year ago. License revenue fell to USD 0.1 million from USD 70.0 million, and collaboration revenue rose to USD 1.0 million from USD 0.6 million. Total revenue therefore declined 63.5% year over year, purely because of the prior-period license payment. Management said more than 100 patients had started veligrotug therapy in the United States by September 30.
Cost of revenues was USD 1.5 million, of which USD 1.3 million was royalties owed to AbbVie, plus amortization of a USD 10.0 million milestone intangible triggered by the approval.
Spending Shifts From Trials to Launch
Operating expenses totaled USD 129.2 million, up from USD 110.6 million. Research and Development spending fell 18.7% to USD 70.1 million as late stage trial and Manufacturing costs for the thyroid eye disease program dropped USD 31.3 million. Direct spending on FcRn inhibitors rose USD 4.2 million, and other research costs, mainly the TSHR program, rose USD 5.9 million.
Selling, general and administrative expense rose 136.9% to USD 57.6 million. Personnel costs added USD 23.2 million on commercial hiring, and professional fees added USD 8.7 million for launch activities. Loss from operations widened to USD 103.5 million from USD 40.0 million, and net loss reached USD 101.2 million, up from USD 34.6 million.
Balance Sheet and Pipeline Milestones
The company held USD 955.2 million in cash, cash equivalents and marketable securities, and the accumulated Deficit stands at USD 1,671.7 million. In May it raised USD 250.0 million of 1.75% convertible senior notes due 2032 and used USD 55.1 million of the proceeds to repay the Hercules term loan. It also carries a revenue participation arrangement with DRI that is accounted for as debt.
The development calendar is full. The company targets a BLA submission for the subcutaneous candidate elegrobart in the first quarter of 2027, after both REVEAL phase 3 studies met their primary endpoints. It is scheduled to share development plans for its FcRn inhibitor portfolio in the fourth quarter of 2026, with phase 1 data for its half-life extended FcRn candidate also targeted for that quarter. The company states that operating losses may continue while it builds clinical, manufacturing and commercial capabilities, and that quarterly revenue could fluctuate with launch uptake and milestone timing.
Guidance Versus Reported Results
Revenue of USD 25.75 million compares with the USD 5.09 million estimate, a gap of USD 20.66 million, while the USD 0.81 loss per share compares with a USD 1.02 estimate. Operating expenses of USD 129.2 million exceed revenue by roughly five times, and the USD 101.2 million net loss compares with USD 34.6 million a year ago. Cash of USD 955.2 million stands against nine month net loss of USD 333.2 million. The company issued no numeric financial guidance.






Please wait processing your request...